"The products and market position of CMS are highly complementary to Elekta's corporate structure, technology portfolio, and R&D roadmap. Both Elekta's and CMS customers will benefit from our combined strength in product development and support. With CMS in the Elekta Group, we will also gain relationships with a large number of customers who do not use Elekta's products today," explains Tomas Puusepp, President & CEO of Elekta. "Elekta and CMS share a common belief in open systems, and a vision that radiation treatment planning is a critical piece of the technology required for emerging radiation therapy treatment capabilities such as VMAT and adaptive therapy. Together, CMS and Elekta can offer and further develop solutions that optimize clinical workflow while also providing well-defined interfaces that allow clinicians to choose systems that best fit their specific needs."
New trends in radiation therapy planning
"The radiation therapy discipline continues to advance and radiation
therapy planning, along with treatment delivery and management technology,
enables clinicians to develop and deliver regimens that hopefully will
result in improved treatment outcomes," explains James P. Hoey, EVP Product
Creation at Elekta and CEO of IMPAC Medical Systems, an Elekta company.
"Elekta recognizes that treatment planning is rapidly evolving from an
event that typically occurred in an isolated area one or two times during
the therapy process to becoming a more iterative process that evolves
throughout the course of therapy with various steps taking place in
different areas of the department. Our aggressive development of MOSAIQ(TM)
RTP as the world's first distributed toolset for advanced radiation therapy
is targeted to meet this growing demand. CMS, with several leading
solutions already in clinical use, and a strong pi
|SOURCE Elekta, Inc.|
Copyright©2008 PR Newswire.
All rights reserved